Supplier Product Identification Physical and Chemical Properties First Aid Measures Handling and Storage Hazards Identification Exposure Controls/Personal Protection Fire Fighting Measures Accidental Release Measures Stability and Reactivity
Home > 1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate > 1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate(75330-75-5)

1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate(75330-75-5)

Supplier Product Identification Physical and Chemical Properties First Aid Measures Handling and Storage Hazards Identification Exposure Controls/Personal Protection Fire Fighting Measures Accidental Release Measures Stability and Reactivity
More
Less

Product Identification

Product Name

1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate

Synonyms

[(1S,3R,7R,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-oxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate
1,2,6,7,8,8a-Hexahydro-beta,delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutyoxy)-1-naphthaleneheptanoic acid delta-lactone
2beta, 6alpha-Dimethyl-8alpha-(2-methyl-1-oxobutoxy)-mevinic acid lactone
Mevinacor
Paschol
Rovacor

CAS

75330-75-5

Formula

C24H36O5

Molecular Weight

404.55

RTECS

EK7907000

RTECS Class

Drug; Reproductive Effector; Human Data

Merck

12,5616

Beilstein/Gmelin

3631989

More
Less

Physical and Chemical Properties

Appearance

White crystals.

Solubility in water

insoluble

Melting Point

174.5 (under nitrogen)

Usage

Medication.

More
Less

First Aid Measures

Ingestion

Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended.

Inhalation

If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention.

Skin

Remove contaminated clothing. Wash exposed area with soap and water. If symptoms persist, seek medical attention. Launder clothing before reuse.

Eyes

If symptoms develop, immediately move individual away from exposure and into fresh air. Flush eyes gently with water for at least 15 minutes while holding eyelids apart; seek immediate medical attention.

More
Less

Handling and Storage

Storage

Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage.

Handling

All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood.

More
Less

Hazards Identification

Skin

Dermatitis, photosensitivity, and dermatomyositis may occur following therapy with hmg-coa reductase inhibitors.

Ingestion

Diarrhea and flatulence were commonly reported adverse effects during clinical trials. Pancreatitis was associated with gemfibrozil-lovastatin combined therapy.

More
Less

Exposure Controls/Personal Protection

Personal Protection

Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots.

Respirators

Use NIOSH/MSHA approved respirator appropriate for exposure of concern.

Exposure Effects

peripheral neuropathies have been reported following therapy with the hmg-coa enzyme inhibitors. Therapeutic administration of hmg-coa enzyme inhibitors may cause insomnia, behavioral changes, and extrapyramidal symptoms. Congenital abnormalities were reported in an infant whose mother ingested dextroamphetamine and lovastatin during the first trimester. <br>Skeletal abnormalities of the ribs and vertebra have been reported in female rats administered lovastatin 800 mg/kg/day during gestation. <br>Animal studies indicate HMG-CoA enzyme inhibitors are excreted into breast milk.

More
Less

Fire Fighting Measures

Fire Fighting

Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire.

More
Less

Accidental Release Measures

Small spills/leaks

Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces.

More
Less

Stability and Reactivity

Stability

No data.

Incompatibilities

Strong oxidizing agents.

More
Less

ContactMore

Chongqing Daxin Pharmaceutical Co.,Ltd.
Tel
023-61301919
Fax
0086-23-61301826
WebSite
http://www.daxinpharm.com
Guangzhou Isun Pharmaceutical Co., Ltd
Tel
020-39119399
Fax
020-39119999
WebSite
http://www.isunpharm.com
Hubei widely chemical technology Co., Ltd.
Tel
027-83989310
Fax
027-83989310
WebSite
http://www.widelychemical.com
J & K SCIENTIFIC LTD.
Tel
010-82848833
Fax
86-10-82849933
WebSite
http://www.jkchemical.com
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
021-61259108
Fax
86-21-61259102
WebSite
https://www.meryer.com/cn/index/